INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,429 as of Tuesday, March 19, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,094 issues advancing vs. 1,811 declining with 142 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 2.0%, Alexion Pharmaceuticals ( ALXN), down 1.4%, Gilead ( GILD), down 1.3%, Celgene Corporation ( CELG), down 0.8% and Teva Pharmaceutical Industries ( TEVA), down 0.6%. Top gainers within the sector include HCA Holdings ( HCA), up 1.6%, Novartis ( NVS), up 1.2% and Shire ( SHPG), up 1.1%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector lower today:

4. Incyte ( INCY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Incyte is down $1.43 (-6.0%) to $22.36 on heavy volume Thus far, 1.7 million shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $22.22-$24.00 after having opened the day at $23.84 as compared to the previous trading day's close of $23.79.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.3 billion and is part of the drugs industry. Shares are up 43.2% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full Incyte Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Pharmacyclics Incorporated ( PCYC) is down $2.65 (-2.9%) to $87.45 on light volume Thus far, 209,858 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 638,300 shares. The stock has ranged in price between $87.21-$90.47 after having opened the day at $89.71 as compared to the previous trading day's close of $90.10.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.3 billion and is part of the drugs industry. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 55.9% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pharmacyclics Incorporated Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Edwards Life ( EW) is down $1.79 (-2.2%) to $79.42 on heavy volume Thus far, 927,661 shares of Edwards Life exchanged hands as compared to its average daily volume of 954,300 shares. The stock has ranged in price between $79.30-$81.37 after having opened the day at $81.14 as compared to the previous trading day's close of $81.21.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $9.4 billion and is part of the health services industry. The company has a P/E ratio of 33.1, above the S&P 500 P/E ratio of 17.7. Shares are down 9.9% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Edwards Life a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Edwards Life Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Agilent Technologies ( A) is down $0.80 (-1.9%) to $41.75 on heavy volume Thus far, 3.5 million shares of Agilent Technologies exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $41.69-$42.82 after having opened the day at $42.68 as compared to the previous trading day's close of $42.55.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $14.9 billion and is part of the health services industry. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 3.9% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null